JNJ-87189401
JNJ-87189401 is an experimental costimulatory agent from Janssen Research & Development in phase 3 trials for prostate cancer, aimed at PSMA.
Overview
JNJ-87189401 is a costimulatory agent developed by Janssen Research & Development. Its target is PSMA (the sponsor names PSMA / CD28). The sponsor states: A PSMA-CD28 costimulatory agent intended to enhance T-cell activation via PSMA engagement plus CD28 costimulation. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07164443 (A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)), in prostate cancer. The largest, NCT07164443, plans to enrol 1203 participants with primary completion expected 2028-08-18. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A PSMA-CD28 costimulatory agent intended to enhance T-cell activation via PSMA engagement plus CD28 costimulation. Connects to PSMA.
1.One arm of JNJ-87189401 binds PSMA on the cancer cell.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"JNJ-87189401" OR ABSTRACT:"JNJ-87189401") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JNJ-87189401, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialA Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Shares PSMA, Prostate cancer and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares PSMA, Prostate cancer and the tag pipeline.
- TrialA Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Shares PSMA, Prostate cancer and the tag pipeline.
- TrialA Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Shares PSMA, Prostate cancer and the tag pipeline.
- TrialA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Shares PSMA, Prostate cancer and the tag pipeline.
- AgentHRS-4357
Shares PSMA, Prostate cancer and the tag pipeline.
- AgentAAA817
Shares PSMA, Prostate cancer and the tag pipeline.